Settlement Date Short Interest Avg Daily Share Volume Days To Cover
6/15/2016 4,478,552 370,020 12.103540
5/31/2016 4,625,048 486,790 9.501115
Short Interest is Dropping!
Yikes! 12 Days to Cover!
Best News All Weekend!
50 mins ·
Earlier this month at #ASCO16, Dr. Heather Wakelee presented an abstract that included our urine-based liquid biopsy test, Trovera, which brought new insights to the liquid biopsy field. Missed the session? Find out from our VP of Research Development, Vlada Melnikova, why this data is so important!
Highly Respect Stock Guru!
His Picks are Early and 80% Accurate!
Bill Patalon thinks $50 is doable for TROV!
Smile and be Happy!
Now we have James Altucher and William Patalon Onboard TROV Train!
Nasdaq: TROV), biotech-sector executive Tina Nova wrote in a Wired magazine essay that the still-in-development cancer-screening technology is "the most exciting thing I've seen since I started my career."
Look Who's Talking… About Liquid Biopsy Technology
By William Patalon III, Executive Editor, Money Morning • June 23, 2016
William Patalon III
I've told this story before, but it bears repeating here...
Back in April 2015, about a month after I originally recommended "Liquid Biopsy" stock TrovaGene Inc. (Nasdaq: TROV), biotech-sector executive Tina Nova wrote in a Wired magazine essay that the still-in-development cancer-screening technology is "the most exciting thing I've seen since I started my career."
This is premium content for Private Briefing subscribers only.
As the executive editor of Money Morning, Bill Patalon has perfected a secret investment strategy that could help you put an extra $125K into your portfolio - this year. To date, Bill has used this strategy to pick 257 winning investments, including 192 double- and triple-digit peak gains. Once you see the secret, you'll immediately understand why it works so well.
59 mins ·
Still have questions after ASCO about the value of liquid biopsies? Check out this video from Targeted Oncology as Dr. Heather Wakelee recaps the data she presented at ASCO about liquid biopsies and EGFR mutations in non-small cell lung cancer patients: http://bit.ly/1QbtTup
Use of Liquid Biopsies for Patients With EGFR-Mutated Non–Small Cell Lung Cancer
Heather A. Wakelee, MD, associate…
James Altucter Says $70 Per Shr for TROV!
Article: June 2016
News Keeps Getting Better!
Anemic Volume Really Doesn't Tell the Story!
Liquid Biopsy @Liquid_Biopsy 23 hours ago
PIPER CMS PAMA: "We believe $TROV Trovagene currently uses a generic CPT code, which could see #reimbursement #declines from PAMA"